

Clinical and Economic Implications of the Most Serious Infections Caused by Resistant Pseudomonas and ESBL Producers: Role of New Options

Thursday, 22 March 2018

09:00 – 10:30

Satellite Symposium
Sponsored by MSD

Swedish Exhibition &
Congress Centre
Room: G4, Level 2
Gothenburg, Sweden

Chair: David Nicolau, PharmD, FCCP, FIDSA

CHAIR

David Nicolau,
PharmD, FCCP, FIDSA

Center for Anti-Infective Research
and Development
Hartford Hospital
Hartford, Connecticut, USA

FACULTY

Rafael Cantón, PhD

Head of Clinical Microbiology
Department
Hospital Universitario Ramón y Cajal
Madrid, Spain

Yoav Golan, MD

Division of Geographic Medicine
and Infectious Disease
Department of Medicine
Tufts Medical Center
Boston, Massachusetts, USA

AGENDA

09:00 – 09:05	Welcome and Introduction	David Nicolau
09:05 – 09:25	How Does the Surrounding Environment Affect My Choices?	Rafael Cantón
09:25 – 09:50	Shifting the Paradigm in Timing and Choice of Therapy for Resistant Gram-Negative Infections	Yoav Golan
09:50 – 10:15	Real-World Evidence and Clinical Data; Appropriate Antibiotic Therapy for Gram-Negative Infections in the ICU	David Nicolau
10:15 – 10:30	Discussion and Q&A	Faculty